CSL has signed a definitive agreement for the acquisition of all publicly held stakes of Switzerland-based Vifor Pharma in a deal worth $11.7bn (A$16.4bn) in cash.
The company will launch a tender offer of $179.25 per share of Vifor Pharma.
The major shareholder holder of Vifor Pharma, Patinex AG, has agreed to tender its stakes in the company.
CSL intends to fund the takeover through a $4.5bn (A$6.3bn) fully underwritten placement, $6bn (A$8.4bn) in a new debt bridge facility and $2bn (A$2.8bn) cash on hand.
The acquisition of Vifor Pharma will aid CSL in diversifying its portfolio by adding ten commercialised products. They include Ferinject / Injectafer, Venofer, Veltassa and Korsuva.
On closing the deal, the merged firm will have an extended pipeline comprising 37 products at various stages of development, up from 37% of CSL’s existing standalone pipeline.
Nealy four products are scheduled to launch next year and in 2023.
Furthermore, the deal complements the current therapeutic focus regions of CSL that include haematology and thrombosis, cardiovascular-metabolic and transplant.
Leave a Reply